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ABSTRACT (No length limit fixed by JEADV) 
BACKGROUND:  In recent years, photodynamic therapy (PDT) has gained increasing 
interest in the treatment of skin cancers and is competing with standard therapeutic 
strategies. 
OBJECTIVE: The objective of this study was to compare the efficacy and cosmetic outcome 
of PDT with methyl aminolevulinate (MAL-PDT) with simple excision surgery for superficial 
BCC (sBCC) over a one year period. 
METHODS: This was a prospective, multicentre, randomised, controlled, open study. Patients 
were treated at baseline either with MAL-PDT (2 treatment sessions 7 days apart, repeated 3 
months later for lesions with incomplete clinical response) or elliptical excision surgery with 
3mm margin (at baseline). Primary endpoints were clinical lesion response 3 months after last 
treatment and cosmetic outcome assessed by the investigator 12 months after last treatment. 
Secondary endpoints were clinical lesion response at 12 months (i.e. recurrence), cosmetic 
outcome assessed by the investigator at 3 and 6 months and by the patient at 3, 6 and 12 
months after last treatment. 
RESULTS:  A total of 196 patients were randomised in a 1:1 ratio to MAL-PDT or surgery, 
with 1.4 sBCC lesions on average per patient. Mean lesion count reduction 3 months after 
last treatment was 92.2% with MAL-PDT versus 99.2% with surgery (PP population) 
confirming the non inferiority of MAL-PDT compared to surgery (95%CI [-12.1;-1.9]). In terms 
of lesion response, 118/128 lesions (92.2%) showed complete clinical response at 3 months 
with MAL-PDT versus 117/118 (99.2%) with surgery (PP population). At 12 months, 11/118 
lesions (9.3%) recurred with MAL-PDT and none with surgery. Cosmetic outcome, whether 
assessed by the investigator or by the patient, was statistically superior for MAL-PDT at all 
time points. Twelve months after last treatment, 96/102 lesions (94.1%) treated with MAL-
PDT had an excellent or good cosmetic outcome as judged by the investigator compared with 
70/117 (59.8%) with surgery. When assessed by the patients, this remained in favour of MAL-
PDT compared to surgery (98/100 [98.0%] and 95/115 [82.6%], respectively). The proportion 
of excellent cosmetic outcome markedly improved with time in the MAL-PDT group whereas it 
remained almost unchanged in the surgery group.  
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CONCLUSIONS: MAL-PDT offers the advantage of a similarly high efficacy and a much 
better cosmetic outcome than simple excision surgery in the treatment of sBCC. 
 
Key words: methyl aminolevulinate, photodynamic therapy, superficial basal cell carcinoma, 
recurrence, cosmetic outcome, surgery.  
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INTRODUCTION 
Basal cell carcinoma (BCC) is the most common malignant neoplasm in fair-skinned people in 
Western industrialized countries. It comprises approximately 70 to 80% of all skin cancers in 
North America1. BCC is classified together with squamous cell carcinoma (SCC) as 
nonmelanoma skin cancer (NMSC). NMSC affects 1-2% of the population annually.2,3 In the 
USA, 0.9-1.2 million estimated new cases of NMSC are diagnosed each year and of these 
80% are BCC2 . In Australia, depending on the regions, the incidence ranges from 729 per 
100,000 individuals to twice this figure.3 
In Europe, published data report incidence of NMSC to be higher in the Northern countries 
than in the Mediterranean area with figures ranging from 24/11 (males/females) per 100,000 
in Spain to 153/114 in the United Kingdom.4 
BCCs can be divided into three major groups, superficial, nodular and infiltrating 
morpheaform lesions. They rarely metastasize but can induce significant local tissue 
destruction and disfigurement. Nodular BCCs (nBCC) account for 60% of all BCCs and 
superficial BCCs (sBCC) account for most of the remainder. sBCCs are slow growing 
cancers, occurring mostly on the trunk in men, and on the head or legs in women.5,6,7,8 It has 
been suggested that intermittent sun exposure may be an etiologic factor in superficial BCC 
as compared with chronic sun exposure in nodular BCC.7 However, so far, this has not been 
clearly established9.  
Current modalities in the treatment of BCC include surgical techniques (surgical excision, 
curettage and electrodesiccation, Mohs micrographic surgery, and cryosurgery), nonsurgical 
interventions (photodynamic therapy, radiotherapy) and pharmacologic treatments (topical 5-
fluorouracil and imiquimod).10,11 The treatment used depends on the type, size, depth and 
localisation of the BCC lesion. 
For the treatment of superficial BCC, surgical excision surgery is generally regarded as the 
treatment of choice. However, one disadvantage of surgical excision is lack of precision in 
margin control. Indeed, in order to avoid incomplete excision, removal of normal tissue 
Kommentar [Zeina1]:  
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with Telfer guidelines (BJD, 1999), 
this is stated in most articles. 
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surrounding the tumour margins is needed.112 Such a technique needs to be performed by an 
experienced dermatologist or by a surgeon.  
In addition, a relationship between incomplete excision of tumor margins and recurrence risk 
was demonstrated11,12,13 adding further to surgery issues.  
Recently, there has been an increased interest in the use of topical photodynamic therapy 
(PDT) for the treatment of skin cancer14. PDT is a non-invasive treatment option which 
involves two major steps: (i) preferential absorption and accumulation of photodynamically 
active porphyrins in neoplastic tissue; and (ii) illumination with a specific light source leading 
to the release of reactive oxygen species within the target tissue.15 The subsequent 
destruction of the targeted cells occurs by apoptosis or necrosis. 
In the treatment of NMSC, topical PDT has the advantage of being limited to the application 
site and illumination field. More importantly, the photosensitiser is preferentially retained in the 
tumour tissue. The selectivity depends on the photosensitizing agent used. As there are no 
cumulative toxic effects, such as with radiation therapy, treatment can be repeated. 
PDT with topical methyl aminolevulinate (MAL-PDT) has been approved in Europe, Australia 
and New Zealand for the treatment of actinic keratoses, BCCs (nodular and superficial) and, 
in some countries, for Bowen’s disease. Numerous published studies have shown the benefit 
of MAL-PDT in terms of efficacy, safety, cosmetic outcome and patient satisfaction in these 
indications.16-24 
One study in particular has been performed comparing MAL-PDT to surgery in patients with 
nodular BCC.19 This study showed an excellent cure rate for MAL-PDT, comparable to 
surgery (respectively 92% and 98% of patients with clinical complete response rate at three 
months after last treatment), and a superior cosmetic outcome for MAL-PDT. However, a 
trend for higher recurrence rate was observed at 24 months with MAL-PDT. 
In another study, comparing MAL-PDT to cryotherapy for the treatment of superficial BCC,24 
MAL-PDT proved as effective as double freeze-thaw cryotherapy, with lesion complete 
response rate of 97% for MAL-PDT vs 95% for cryotherapy three months after last treatment. 
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Long term efficacy was also demonstrated with cumulative recurrence rates of 22% for MAL-
PDT versus 20% for cryotherapy at the end of a five-year follow-up period. At that time, 
notably more patients had excellent cosmetic outcome with MAL-PDT (56%) than with 
cryotherapy (14%).  
However, no comparison was made between MAL-PDT and the gold standard, surgery, in the 
treatment of superficial BCC. The aim of this prospective, multicentre, randomized, controlled, 
parallel-group, open study was to compare the efficacy, safety, and cosmetic outcome of 
MAL-PDT with simple excision surgery for the treatment of superficial BCC over a one-year 
period. 
 
METHODS 
Study design 
The study was performed in accordance with Good Clinical Practices and in compliance with 
local regulatory requirements. The appropriate national authorities and local Ethics 
Committees approved the protocol before study commencement. All patients provided written 
informed consent before inclusion into the study. 
This was a multicentre, controlled, randomized, open, parallel-group clinical trial performed 
between August 2004 and November 2006. Twenty seven (27) investigator centres 
participated in the study: 10 in the United Kingdom, 10 in Germany, 2 in Switzerland and 5 in 
Australia. 
The objectives of the study were to show a non-inferior efficacy of MAL-PDT compared to 
surgery in terms of lesion response 3 months after last treatment, and a superiority of MAL-
PDT over surgery in terms of cosmetic outcome 12 months after last treatment. 
 
Patients 
Kommentar [Zeina2]: This is 
the only part of the article where the 
objectives of the study are precisely 
stated. Therefore, I left this 
paragraph as it was. 
Page 8 of 29 
29040 manuscript for JEADV 
October 4th, 2007 
Eligible patients were males or females older than 18 years with a clinical diagnosis of 
primary superficial BCC, suitable for simple excision surgery, confirmed by histology and with 
no histological evidence of aggressive growth patterns. Excluded from the study were patients 
with more than five eligible lesions; lesions located in the mid-face region (nose, nasolabial or 
orbital areas); lesions with a largest diameter less than 8 mm or more than 20 mm; recurrent 
lesions; lesions located in severely sun-damaged skin where surgery was not suitable due to 
frequent recurrence/occurrence of other BCCs in the same area; lesions located close to or 
involving a scar of Squamous Cell Carcinoma; pigmented, morpheaform or infiltrating lesions 
on the treated area. Patients who were at risk in terms of precautions, warnings, and 
contraindications as indicated in the package insert for MAL-PDT as well as women who were 
pregnant or breastfeeding were excluded. Concurrent use on the study treatment areas of 
cryotherapy, surgery, 5 fluorouracil, radiotherapy, aminolevulinate based photodynamic 
therapy (ALA-PDT), imiquimod, electrodessication or curettage was prohibited. 
 
Treatments 
At screening, a biopsy was performed for histological confirmation of the lesions. Biopsy was 
not required if a histological report dated from less than 6 months was available. 
Within four weeks of the screening visit, eligible patients were randomised consecutively to MAL-
PDT or excision surgery. Treatment assignment was done at each investigator site: at study 
initiation, a block of numbered randomisation cards was provided to each site; whenever a 
patient was considered eligible, the investigator had to scratch a randomization card, 
following an ascending number order, to disclose the procedure assigned to the patient. The 
date and time of disclosure were documented to ensure randomisation order was respected. 
Patients randomised to MAL-PDT were treated with one cycle of 2 treatment sessions 7 days 
apart. sBCC lesions showing non complete response 3 months later could be retreated with a 
second cycle of 2 MAL-PDT sessions 7 days apart. Prior to each PDT session, if deemed 
necessary, the sBCC lesions were prepared, without bleeding or pain, to remove scales and 
crusts and roughen lesion surface. Then, a layer of about 1mm thick of MAL 160mg/g cream 
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(Metvix, Galderma SA, Lausanne, Switzerland – PhotoCure ASA, Oslo, Norway) was applied 
to the lesion and the surrounding 5-10mm of normal skin. The treated area was covered with 
an occlusive dressing for 3 hours then washed off with saline solution. Subsequently, lesions 
were exposed to red light using a large-field LED light source (AktiliteTM CL 128 or CL 16, 
Galderma SA, Lausanne, Switzerland – PhotoCure ASA, Oslo, Norway) during 7 to 10 minutes 
to deliver a total dose of 37 J/cm². Mini desk fans were provided to the centres to cool the 
irradiation sites during red light exposure. 
For patients randomised to surgery, one simple elliptical excision surgery was performed at 
baseline according to the investigators routine practice with a 3-mm margin from the clinically 
estimated edge of the lesion. The excised specimen was sent for histological examination. 
 
There was a 12-month follow-up period after last treatment procedure in both groups. 
Therefore, the duration of the study for each patient was 13 to 16 months depending on 
whether one or two MAL-PDT cycles were required. For patients who received one MAL-PDT 
cycle and for those who underwent surgery, study visits took place at screening, baseline, 
Week 1, Week 13, Month 6 and Month 12, and a safety follow-up phone call was given at 
Week 3. For patients who required two MAL-PDT cycles, additional visits took place at Week 
14, Month 9 and Month 15, and a phone call was scheduled at Week 15. 
Lesions showing an incomplete clinical response 3 months after last treatment were not 
assessed during the subsequent visits and it was the responsibility of the investigator to 
consider the best alternative therapy. 
 
Outcome measures 
For the sake of simplification, results ‘3, 6 and 12 months after last treatment’ are stated 
hereafter as results ‘at 3, 6 and 12 months’.  
 
The primary outcomes were the clinical lesion response at 3 months [complete response 
(CR): complete clearance of the lesion, non complete response (non CR): non complete 
Page 10 of 29 
29040 manuscript for JEADV 
October 4th, 2007 
clearance of the lesion], and the cosmetic outcome assessed by the investigator at 12 months 
on a 4-point scale (0: poor, 1: fair, 2: good, 3: excellent). 
The secondary outcomes were: lesion recurrence at 12 months; cosmetic outcome assessed 
by the investigator at 3 and 6 months; cosmetic outcome assessed by the patient at 3, 6 and 
12 months on the same 4-point scale as above. 
Adverse events, whether reported spontaneously by the patient or elicited following non-
leading questioning, were recorded at each visit together with their severity, duration and 
need for additional therapy. Investigators were asked to list under photosensitivity reaction 
expected reactions such as skin discomfort, burning sensation, erythema, stinging, among 
others, reported with MAL-PDT. 
 
Statistical methods 
Based on published data on the efficacy of simple excision surgery in nodular BCC19, it was 
assumed that in the present study, this modality would lead to a 90% reduction in lesion count 
and that the response to MAL-PDT would be the same. The largest clinically acceptable 
difference in terms of percent reduction in lesion count 3 month after the last treatment was 
15%. If the lower limit of the confidence interval of the difference (MAL-PDT – simple excision 
surgery) was above -15%, MAL-PDT was considered non-inferior to simple excision surgery. 
In terms of cosmetic outcome, based on the results of the same published study, it was 
decided to set a 40% minimal difference in favour of MAL-PDT over simple excision surgery. 
If the p-value was below 0.05 and the difference positive, then MAL-PDT was declared 
superior to simple excision surgery. 
With an assumed 90% reduction in lesion count with simple excision surgery, a two-sided 
95% confidence interval for the difference between groups, an alpha risk set at 5% two sided 
and a power of approximately 90%, it was calculated that 84 patients would be necessary per 
group. With this number of patients the power would be around 99% for the cosmetic 
outcome, and the overall power on this study (intersection of the two alternative hypotheses) 
would be around 90% on this trial. Assuming a 15% rate of non-evaluable patients, a total of 
198 patients needed to be enrolled (99 patients in each group). 
Kommentar [Zeina3]: This 
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To analyse the lesion response, the percent reduction in lesion count per patient was 
calculated to compare both treatments. The percent reduction in lesion count was submitted 
to a weighted analysis of variance including treatment effect. The analysis of variance was 
weighted by number of treated lesions per patient at baseline. The 95% Confidence Interval 
was calculated from the weighted analysis of variance on the per protocol (PP) population. 
Intent-To-Treat (ITT) analysis using the Worst Case scenario (all missing values were 
considered as Non Complete Response) was also performed to assess the robustness of the 
results obtained on the PP population. Additionally, the lesion response rate (Complete 
Response/Non Complete Response) 3 months after the last treatment and the recurrence 
rate after 12-month follow-up were descriptively presented by treatment. 
To analyse the Cosmetic outcome, a success/failure rate (dichotomous variable) was 
calculated to compare both treatments. Success per patient was defined as a mean across 
lesions scored greater or equal to 2 (at least good cosmetic outcome). The superiority of 
MAL-PDT over simple excision surgery was demonstrated by showing a significant difference 
between these two groups for the success/failure rate using a Cochran-Mantel-Haenszel test 
(CMH) stratified by centre with the ridit transformation and the row mean scores option on all 
data observed. Tests were two-sided and significance was declared at a 5% threshold. 
Additionally, the cosmetic outcome score (full scale, from Poor to Excellent) 12 months after 
the last treatment and the improvement rate from the month-3 after the last treatment were 
descriptively presented by treatment. 
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RESULTS 
Patient disposition and baseline characteristics 
Out of the 234 screened patients, 196 had positive histology confirming sBCC diagnosis and 
were enrolled: 100 patients were randomised to MAL-PDT and 96 patients to surgery. Two 
thirds of the patients were males. The mean age was 63.8 years, ranging from 31 to 92 years. 
All patients were Caucasians. Baseline demographic characteristics were comparable in the 
two treatment groups (Table 1). 
On average in both groups, patients had 1.4 lesions. Most patients in each group had one 
lesion (79/100, 79% in the MAL PDT group and 77/96, 80.2% in the surgery group). In both 
groups, the majority of lesions were located on the trunk/neck. A slight unevenness could be 
observed between the two treatment groups in terms of lesion location. Indeed, there were 
slightly more lesions on the face/scalp in the MAL-PDT group than in the surgery group 
(Table 1). 
Patient disposition is depicted in Figure 1. Overall, 173/196 patients (88.3%) completed the 
study. Few major deviations were observed. Fourteen patients (7.1%) were considered non 
eligible for the PP analysis. There were more patients with at least one major deviation in the 
surgery group than in the MAL-PDT group (10/96 [10.3%] vs. 4/100 [4.0%], respectively). The 
most frequent major protocol deviation was lack of post baseline data or lack of efficacy data 
at 3 months: 4/100 patients (4.0%) in the MAL-PDT group and 8/96 patients (8.3%) in the 
surgery group. The PP population included 182 patients (92.9%). 
MAL-PDT procedure 
Overall, about 90% of the lesions were prepared before cream application for the first cycle 
(baseline and week 1), and about 85% at the second cycle. The mean time of cream 
application was 3:05 hours with a mean illumination time necessary to deliver the required 
dose of 8:22 minutes. No patients needed to have illumination stopped and restarted due to 
pain at the first session of both cycles, and only 3% of the patients needed so at the second 
session of each cycle (4/133 patients at week 1 and 1/35 patient at week 14). 
 
Kommentar [Zeina5]: This 
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Surgery 
After surgical resection, 8/125 specimens (6.4%) showed a histologically positive margin. For 
all of them, no further surgery was made and patients remained in the study as it is standard 
of care in sBCC. 
Clinical lesion response 
At 3 months, both treatments showed a high percentage reduction in lesion count by patient: 
92.2% mean lesion count reduction with MAL-PDT versus 99.2% with surgery (PP 
population). The 95% C.I. lower limit of the difference between treatments was -12.1% 
confirming that MAL-PDT was non inferior to surgery (within the pre-specified margin of -
15%). In terms of lesion response, 118/128 lesions (92.2%) showed complete clinical 
response at 3 months with MAL-PDT versus 117/118 (99.2%) with surgery (PP population). 
The observed results followed the same trend irrespective of lesion size or location except for 
lesions located on face/scalp which complete response rate was 100% in the MAL-PDT group 
(Table 2). The analysis on the ITT population confirmed the PP analysis. 
Overall, 91/128 lesions (71.1%) had been treated with only one cycle of MAL-PDT, 
representing 76.3% (90/118) of the cleared lesions. 
Among the lesions showing complete clinical response at 3 months, 9.3% of lesions (11/118) 
recurred at 12 months in the MAL-PDT group and none in the surgery group (0/117). See 
Table 3 for details per location. 
Cosmetic outcome 
Whether assessed by the investigators or by the patients, the cosmetic outcome of cleared 
lesions was statistically superior with MAL-PDT than with surgery at each visit after last 
treatment. At 12 months, per the investigator’s assessment, 77/83 patients (92.8%) in the 
MAL-DT group vs. 44/86 (51.2%) of patients in the surgery group (p<0.001) were considered 
“success”, i.e. mean cosmetic outcome across lesions at least good. 
The proportion of lesions showing excellent cosmetic outcome was much higher with MAL-
PDT from 3 months, and it substantially improved with time in the MAL-PDT group whereas it 
Kommentar [Zeina6]:  
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remained almost unchanged in the surgery group (Figure 2). No poor cosmetic outcome was 
observed with MAL-PDT at any visit, except for one lesion at 3 months per the patient’s 
assessment.  
An example of the outcomes of MAL-PDT and simple excision surgery is shown in Figure 3.  
Adverse events 
The incidence of treatment related adverse events (AEs) was higher in the MAL-PDT group 
than in the surgery group: in the MAL-PDT group, 37/100 patients (37%) reported 65 related 
AEs versus 14/96 patients (14.6%) with 21 related AEs in the surgery group. Related AEs that 
occurred in at least 2 patients are described in Table 4. Most related AEs were expected AEs 
of dermatological nature: photosensivity reaction for MAL-PDT (31/100 patients [31%] with 57 
AEs), and wound infection for surgery (5/96 patients [5.2%] with 5 AEs). All related AEs were 
of mild or moderate severity, except one severe wound infection reported in the surgery 
group.  
Among the 37 patients with AEs related to MAL-PDT, only 4 (11%) required treatment for 
their AEs, mainly limited use of analgesic or antiseptic drugs, compared to 8 out of the 14 
patients (57%) who reported AEs related to surgery necessitating mostly a 1 to 2-week 
course of systemic antibiotic therapy (5 patients) or repeated intake of analgesics (3 patients). 
A total of 21 serious AEs were reported, none were considered as related to any of the 2 
study procedures. AEs leading to permanent discontinuation of study occurred in 2 patients in 
the MAL-PDT group and in 1 in the surgery group. None of them were treatment-related. 
 
DISCUSSION 
In the treatment of sBCC, this is the only published study comparing topical PDT and simple 
excision surgery, commonly regarded as the treatment of choice in this indication. The 
present results demonstrate that 3 months after last treatment, the efficacy of MAL-PDT is 
comparable to that of surgery in the treatment of sBCC: 92.2% of lesions showed complete 
Kommentar [Zeina7]: This 
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clinical response at 3 months with MAL-PDT versus 99.2% with surgery. However, at 12 
months, 9.3% of lesions recurred with MAL-PDT compared to none with surgery. 
 
Cosmetic outcome of lesions cleared at 12 months, whether assessed by the investigator or 
by the patient, was superior for MAL-PDT over surgery. Twelve months after last treatment, 
93% of patients in the MAL-PDT group vs. 51% of patients in the surgery group had a mean 
cosmetic outcome across lesions scored at least ‘good’ by the investigator. Moreover, 
cosmetic outcome markedly improved with time in the MAL-PDT group, unlike surgery. 
 
In the present study, although side effects observed with MAL-PDT (mainly photosensitivity 
reaction) were notably more frequent than with surgery (mainly wound infection), they were of 
mild to moderate intensity, transient and easily manageable: only 11% of patients required 
their side effects to be treated, and it was with a one-day treatment of analgesic of antiseptic 
drug, while 57% of patients with surgery-related adverse events needed treatment for this, in 
particular with systemic antibiotics. This issue had been previously described with surgery 
and also with cryotherapy.25 
 
Our study was limited to a 12-month follow-up where a longer period would have revealed a 
large number of relapses. However, previous findings on recurrence rates with MAL-PDT at 
12 months24,26 are similar to the 9.3% rate obtained in our study and one might suggest that 
longer follow-up period would have led to recurrence rates comparable to those published24. 
Moreover, it was shown that recurrences with MAL-PDT reach a plateau at 36 months 
dismissing the need for longer observation periods. 
 
The open design of the present study might have constituted a bias. Indeed, though 
randomised treatment allocation was ensured with the system of randomisation cards, and 
with the record of date and time each card was disclosed, the lesion response evaluator could 
identify the allocated treatment modality based on the aspect of the residual wound. 
Moreover, it should be noted that eligible lesions were those considered suitable for simple 
Kommentar [Zeina8]:  
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excision surgery. Therefore, lesions were excluded that where located on areas where MAL-
PDT would have been the most appropriate treatment. 
 
In our study, no histological confirmation of lesion response was required. Response to 
treatment was based on clinical evaluation only, reflecting real-life practice. Nevertheless, it is 
interesting to notice that no recurrence was observed among the 6.4% of lesions with 
histologically positive margins following excision. 
 
The advantages conveyed by MAL-PDT in terms of cosmesis makes this therapeutic modality 
particularly suitable for the treatment of superficial BCC. Indeed, sBCC is a disease of 
relatively low risk and is more frequent in young patients14, and often located on areas prone 
to hypertrophic scarring and/or keloids such as the trunk and legs7,9. In addition, as superficial 
BCCs are often more than 10 mm in diameter before they are diagnosed as such, because 
they first appear to be actinic keratoses or inflammatory lesions, their excision in areas likely 
to show poor healing may lead to scarring or disfigurement or require skin grafts, with 
potential significant psychological impact. This aspect is supported by a discrete-choice 
experiment conducted with members of the Australian general public, which found that 
patients are willing to pay for the better cosmetic outcomes provided by MAL-PDT rather than 
receive simple excision for BCC.27 High clearance rates with superior cosmetic outcome 
obtained with MAL-PDT are also of great interest for the treatment of extensive and multiple 
lesions. In a previous study, it was found that cosmetic outcome improved over time in 
difficult-to-treat populations who might be expected to have poor cosmetic outcomes.28  
 
Another interesting feature with MAL-PDT is the ease of re-treatment in case of non complete 
response or recurrence: there is no long term or cumulative toxicity of MAL-PDT and no 
secondary defect or scarring. 
 
In conclusion, in line with international recommendations on the use of PDT for nonmelanoma 
skin cancer14, the results of our study suggest that owing to its high efficacy and excellent 
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cosmetic outcome, MAL-PDT can be considered as an option to surgery in the treatment of 
superficial BCCs. 
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Table 1:  Baseline patient demographics and lesion characteristics (ITT population) 
 
 MAL-PDT 
(N = 100) 
Surgery 
(N = 96) 
Total 
(N = 196) 
Gender  
Male 
Female 
 
n (%) 
 
 
64 (64.0) 
36 (36.0) 
 
66 (68.8) 
30 (31.3) 
 
130 (66.3) 
66 (33.7) 
Age (years) 
 
Mean ± sd  
Range 
64.5 ± 12.7 
33; 85 
63.1 ± 13.9 
31; 92 
63.8 ± 13.3 
31; 92 
Race 
 
 
Caucasian   n (%) 
 
100 (100) 
 
96 (100) 
 
196 (100) 
     
Mean ± sd  1.4 ± 0.8 1.4 ± 0.9 - Lesion 
number per 
patient Min; Max 1; 5 1; 5 - 
Lesion 
distribution 
1 lesion n (%) 
 1 lesion n (%) 
79 (79) 
21 (21) 
77 (80.2) 
19 (19.8) 
- 
 
Lesion 
diameter (mm) 
per patient 
Mean + sd 12.5±3.7 12.6±3.7 - 
Total  135 132 - 
Trunk/neck; n (%) 81 (60) 93 (70.5) - 
Extremities; n (%) 39 (28.9%) 33 (25.0) - 
Lesion 
location 
Face/scalp; n (%) 15 (11.1%) 6 (4.5) - 
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Table 2: Lesion complete response to treatment at 3 months (PP population) 
 MAL-PDT Surgery 
Overall lesion response, N (%) 118 /128 (92.2) 117/118 (99.2) 
Lesion response by location, N (%)   
 Face/scalp 15/15 (100) 4/4 (100) 
 Trunk/neck 69/76 (90.8) 82/83 (98.8) 
 Extremities 34/37 (91.9) 31/31 (100) 
Lesion response by size, N (%)   
 7 – 14 mm 78/85 (91.8) 69/70 (98.6) 
 15 – 20 mm 40/43 (93.0) 43/43 (100) 
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Table 3: Lesion recurrence at 12 months (ITT population) by location 
 MAL-PDT Surgery 
Cleared lesions, N (%)  107/118 (90.7) 117/117 (100) 
Recurred lesions, N (%) 11/118 (9.3) 0/117 (0) 
 Face/scalp 4/15 (26.7) - 
 Trunk/neck 3/69 (4.3) - 
 Extremities 4/34 (11.8) - 
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Table 4: Treatment related adverse events 
 MAL-PDT N=100 
Surgery 
N=96 
Patients with related AEs, N(%) 37 (37) 14 (14.6) 
Most common related AEsa, N(%)  
Photosensitivity reactionb 31 (31) - 
Wound infection - 5 (5.2) 
Erythema - 3 (3.1) 
Post procedural pain - 3 (3.1) 
Pain 2 (2) 1 (1) 
Milia 2 (2) - 
Wound dehiscence - 2 (2.1) 
aReported by at least 2 patients 
b Photosensitivity reaction included all expected reactions such as skin 
discomfort, burning sensation, erythema, stinging, among others, reported with 
MAL-PDT 
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Figure 1: Patient disposition 
 
 
 
 
 
 
Discontinued 
N = 13 (13%) 
 
Adverse Event: 2 (2%) 
Lost to follow-up:  1 (1%) 
Protocol violation: 1(1%) 
Patient’s request: 1 (1%) 
Other: 8 (8%) 
Completed  
the study 
N = 86 (89.6%) 
Completed  
the study 
N = 87 (87%) 
N = 86 
PP population 
Discontinued 
N = 10 (10.4%) 
 
Adverse Event: 1 (1%) 
Patient’s request: 5 (5.2%) 
Other:  4 (4.2%) 
Patients Randomised 
N = 196 
MAL-PDT 
N = 100 
Surgery 
N = 96 
N = 96 
PP population 
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Figure 2: Excellent or good cosmetic outcome over time (observed cases) 
a) as assessed by the investigator 
 
 
b) as assessed by the patient 
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Figure 3: Patient pictures 
 
Lesion treated with one MAL-PDT cycle Lesion treated with surgery 
  
Before treatment 
 
  
After 3 months  
 
  
After 12 months 
 
 
